Vitamin B12 deficiency anemia

Article written and reviewed by Dr Luca Moretti

Vitamin B12 deficiency anemia, also known as megaloblastic anemia due to cobalamin deficiency, is a hematologic condition caused by insufficient availability of vitamin B12 (cobalamin), an essential cofactor in DNA synthesis and in nucleic acid and amino acid metabolism. This form of anemia is characterized by increased red blood cell volume (macrocytes) and a bone marrow picture characterized by megaloblastosis, morphologic abnormalities also involving the granulocytic and platelet lineages, and systemic manifestations affecting not only the hematopoietic system but also the nervous system and gastrointestinal tract.

Vitamin B12 deficiency may result from numerous mechanisms, ranging from intestinal malabsorption (by far the most common cause in industrialized countries) to nutritional deficiencies, congenital abnormalities of cobalamin metabolism and autoimmune conditions such as pernicious anemia. Clinically, the disorder often presents insidiously, with initially subtle symptoms and, in advanced stages, macrocytic anemia, pancytopenia and potentially irreversible neurologic injury if not treated promptly.

Diagnosis requires a careful work-up integrating clinical, laboratory and instrumental data, whereas treatment, based on correcting the deficiency and identifying the underlying cause, can rapidly reverse the hematologic abnormalities and prevent permanent neurologic sequelae, provided that it is instituted promptly.

Etiology and risk factors

Vitamin B12 deficiency has multiple causes, reflecting the complexity of cobalamin metabolism and its dependence on physiologic processes involving the stomach, pancreas, small intestine and liver. Vitamin B12 is naturally present mainly in foods of animal origin, such as meat, eggs and dairy products; fortified foods and supplements are alternative sources. Its absorption requires a multistep pathway involving release from food, binding to intrinsic factor produced by gastric parietal cells, transit through the intestine and absorption in the distal ileum through specific receptors.

Causes of vitamin B12 deficiency include:

• Reduced dietary intake: rare in industrialized countries, prevalent among people following strict vegan/vegetarian diets, people with alcoholism, or people with eating disorders. In children breastfed by unsupplemented vegan mothers, deficiency may present during the neonatal period.
• Gastric malabsorption: mainly due to pernicious anemia (autoimmune atrophic gastritis with destruction of parietal cells and reduced intrinsic factor), but also to total/partial gastrectomy, chronic Helicobacter pylori infection, prolonged use of proton pump inhibitors or H2-receptor antagonists, and age-related gastric atrophy.
• Intestinal malabsorption: conditions that reduce the surface area or function of the distal ileum (Crohn disease, intestinal resections, untreated celiac disease, tropical sprue, Giardia lamblia infection), pancreatic insufficiency (failure to release proteases required to free cobalamin from salivary binding proteins), and Diphyllobothrium latum infestation (fish tapeworm).
• Genetic or congenital abnormalities: inherited disorders of cobalamin metabolism, deficiencies of ileal receptors for the B12-intrinsic factor complex, and congenital defects of plasma transport and cellular uptake (transcobalamin II deficiency).
• Other causes: interfering drugs, particularly metformin, nitrous oxide exposure and rare congenital disorders of cobalamin transport or metabolism.

The main risk factors for vitamin B12 deficiency anemia include:

• Advanced age (higher frequency of atrophic gastritis, reduced acid secretion, reduced dietary intake and polypharmacy).
• Unsupplemented vegan/vegetarian diet and disadvantaged socioeconomic conditions.
• Personal/family history of autoimmune diseases (especially pernicious anemia, thyroiditis, type 1 diabetes and vitiligo).
• Previous gastrointestinal surgery (gastrectomy, ileal resection, bariatric surgery).
• Chronic gastrointestinal diseases (celiac disease, Crohn disease, chronic pancreatic insufficiency).
• Chronic use of interfering drugs (metformin, H2 antagonists, proton pump inhibitors).
• Chronic alcoholism and eating-related disorders.

These factors are not direct causes but conditions that increase susceptibility to cobalamin deficiency, especially when several coexist.

From an epidemiologic standpoint, vitamin B12 deficiency is more frequent in older adults, patients with autoimmune diseases and areas where animal-derived foods are less available. Its natural history is slow and insidious because large hepatic cobalamin stores can provide sufficient supply for several years when intake is reduced.

Pathogenesis and pathophysiology

The pathophysiology of vitamin B12 deficiency anemia results from abnormalities that may affect any stage of the complex pathway of cobalamin assimilation, transport and utilization in the body. Loss of efficiency in even one of these steps causes progressive depletion of body stores and ultimately development of the clinical syndrome. The physiologic sequence of vitamin B12 handling is therefore central to understanding the pathogenetic mechanisms of the disease.

• Dietary intake: vitamin B12 is naturally present mainly in meat, fish, eggs and dairy products, while fortified foods and supplements can provide adequate amounts. In adults, depletion due to insufficient intake is generally slow because of hepatic stores, whereas it may be more rapid in young children and in infants breastfed by deficient mothers.
• Gastric release: after ingestion, cobalamin is bound to dietary proteins and is released through the action of gastric hydrochloric acid and pepsin. Diseases or treatments that reduce gastric acidity (autoimmune atrophic gastritis, gastrectomy, chronic use of H2 antagonists or proton pump inhibitors) can reduce release and absorption of food-bound vitamin.
• Binding to transport factors: the vitamin initially binds to salivary and gastric R proteins; in the duodenum, pancreatic proteases release it, allowing it to bind to intrinsic factor (IF), produced by gastric parietal cells. Defective production or function of IF, as in pernicious anemia or after gastrectomy, impairs formation of the vitamin B12-IF complex and intestinal absorption.
• Ileal absorption: the vitamin B12-intrinsic factor complex reaches the terminal ileum, where it is absorbed through specific receptors. Conditions such as Crohn disease, ileal resections, untreated celiac disease, parasitic infection (Diphyllobothrium latum) and small intestinal bacterial overgrowth can drastically impair this phase.
• Plasma transport: once absorbed, approximately 70-80% of circulating vitamin B12 is bound to haptocorrin, whereas approximately 20-30% is bound to transcobalamin II, which constitutes the biologically available fraction for tissue delivery. Inherited defects of transcobalamin II, although rare, can cause functional deficiency.
• Intracellular utilization: cobalamin is converted into its active forms, methylcobalamin and adenosylcobalamin, to participate in essential enzymatic reactions; congenital defects in intracellular conversion cause functional deficiency even when serum levels are normal.

At the cellular level, vitamin B12 is essential as a cofactor in two fundamental metabolic pathways whose integrity is necessary for both erythropoiesis and nervous system function. Methylcobalamin, one of the two active forms of cobalamin, participates in methylation of homocysteine to methionine, a reaction catalyzed by methionine synthase. This reaction is a critical node in cellular biochemistry because the resulting methionine is rapidly converted to S-adenosylmethionine (SAM), the principal methyl-group donor for numerous methylation processes. Blockade of methionine synthase also causes the so-called “methyl-folate trap”, with accumulation of 5-methyl-THF and reduced availability of tetrahydrofolate for thymidylate and purine synthesis; the resulting impairment of DNA synthesis predominantly affects tissues with rapid turnover such as bone marrow.

In parallel, adenosylcobalamin, the other active form of vitamin B12, acts as a cofactor for methylmalonyl-CoA mutase. This reaction permits conversion of methylmalonyl-CoA to succinyl-CoA, an essential step in the metabolism of odd-chain fatty acids and some branched-chain amino acids through the Krebs cycle. Succinyl-CoA enters the Krebs cycle and participates in multiple biosynthetic pathways. Neurologic injury in vitamin B12 deficiency is multifactorial and is not explained by a simple lack of succinyl-CoA as a myelin precursor; increased methylmalonic acid is primarily a biochemical marker of functional deficiency.

When vitamin B12 availability is reduced, whether because of insufficient intake, impaired absorption, transport defects or genetic blocks in intracellular metabolic pathways, the entire physiology of erythropoiesis is affected. In bone marrow erythroid precursors, methylcobalamin deficiency slows or arrests DNA synthesis, blocking cell division during S phase. Cells nevertheless attempt to mature while continuing cytoplasmic synthesis, resulting in formation of megaloblasts, large cells with a large immature nucleus and mature cytoplasm. Most of these precursors undergo intramedullary apoptosis, producing ineffective erythropoiesis and reducing the availability of mature erythrocytes. Consequently, macrocytic anemia develops, often associated with leukopenia and thrombocytopenia because granulocytic and megakaryocytic lineages, which also have high proliferative rates, are involved.

Impairment of vitamin B12 metabolic pathways also produces measurable biochemical abnormalities: reduced methionine synthase activity causes homocysteine accumulation in blood, whereas blockade of methylmalonyl-CoA mutase causes methylmalonic acid accumulation. Homocysteine and methylmalonic acid are useful metabolic markers of functional cobalamin deficiency. Hyperhomocysteinemia is associated with vascular risk but does not by itself establish causality; the direct neurotoxic role of methylmalonic acid in common acquired deficiency is not defined.

The nervous system is particularly susceptible to the effects of vitamin B12 deficiency. Proposed mechanisms include altered methylation of myelin lipids and accumulation of metabolites related to methylmalonyl-CoA mutase blockade, but neurologic pathogenesis remains incompletely defined. Subacute combined degeneration of the spinal cord preferentially involves the posterior and lateral columns but may also extend to nerve roots and peripheral pathways. Clinical manifestations include paresthesias, ataxia, hypoesthesia, motor weakness and sphincter disturbances, as well as psychiatric symptoms, cognitive deficits and, in advanced cases, subacute dementia. In children and infants, progression may be particularly rapid, causing severe neuromotor deficits and developmental delay if deficiency is not recognized and corrected promptly.

Hyperhomocysteinemia accompanying vitamin B12 deficiency is associated in observational studies with cardiovascular and thrombotic events, but vitamin B12 deficiency has not been shown to be a direct cause of those events, nor has homocysteine reduction been shown to prevent them systematically.

Overall, the pathophysiology of vitamin B12 deficiency anemia represents convergence of multiple mechanisms: defects in vitamin availability and absorption, blocks in intracellular metabolic pathways, impaired DNA synthesis and myelin metabolism, and abnormalities of cobalamin-dependent metabolites. Reversibility of hematologic and neurologic injury depends on prompt diagnosis and restoration of adequate cobalamin levels; chronic or severe deficiency may instead make some complications permanent, particularly neurologic ones.

Clinical manifestations

The clinical picture of vitamin B12 deficiency anemia is characterized by its slow and insidious evolution, the variety of manifestations and frequent dissociation between hematologic and neurologic symptoms. Progression of signs and symptoms is influenced by the duration and severity of deficiency, the underlying cause and the patient's age.

Hematologic manifestations

The classic hematologic picture is macrocytic megaloblastic anemia, often well tolerated in the early stages because of cardiovascular adaptation but progressively worsening. Patients report chronic asthenia, easy fatigability, exertional dyspnea and tachycardia. More advanced cases may present with palpitations, headache, tinnitus, evident skin and mucosal pallor and, in severe anemia, angina pectoris or heart failure in people with pre-existing cardiac disease. Peripheral blood smear typically shows macro-ovalocytes, marked anisopoikilocytosis, hypersegmented granulocytes (with nuclei containing 5 or more lobes), and platelets that are often enlarged but reduced in number. With more prolonged deficiency, pancytopenia may become severe, with neutropenia and thrombocytopenia exposing the patient to infection and bleeding risk. Reticulocytopenia is typical and reflects ineffective erythropoiesis. Mild jaundice (subicterus) is frequent because of increased catabolism of erythroid precursors (indirect hyperbilirubinemia).

Neurologic manifestations

Neurologic symptoms are a distinctive feature and may sometimes be the first sign of deficiency, even in the absence of marked anemia. Onset is often insidious: patients report symmetric paresthesias (tingling, pins and needles) in the hands and feet, a sense of numbness and progressive loss of vibration and proprioceptive sensation (positive Romberg test). As deficiency progresses, sensory ataxia develops with gait instability, muscle weakness especially in the lower limbs, spasticity and hyperreflexia (pyramidal signs). Mixed sensorimotor peripheral neuropathy is not uncommon, with hyporeflexia, distal motor deficits, reduced strength and, in advanced cases, impaired fine movements and sphincter disturbances. Cognitive involvement may manifest with irritability, depression, apathy, emotional lability, psychomotor slowing, memory deficits and, in more severe or chronic forms, subacute dementia and confusional states. In young children and infants, vitamin B12 deficiency is associated with neuropsychomotor developmental delay, hypotonia, somnolence, poor interest in the environment, seizures and regression of acquired motor skills when diagnosis is delayed. In these cases, even a few months of deficiency may leave permanent sequelae.

Gastrointestinal manifestations

Atrophic glossitis (“Hunter's tongue”), with a smooth, red, painful and depapillated tongue, is a frequent and often early sign, accompanied by angular cheilitis, oral burning, altered taste and sometimes oral mucosal ulcers. Patients frequently report anorexia, weight loss, nausea and dyspepsia. Bowel disturbances such as intermittent diarrhea or constipation may be associated with abdominal distension and dull, nonlocalized pain. In pernicious anemia, atrophic gastritis with reduced gastric acidity and malabsorption of other micronutrients is often present. The increased risk of gastric neoplasia (carcinoma and carcinoid tumor) in people with longstanding pernicious anemia should be emphasized.

Systemic manifestations

Hyperhomocysteinemia may accompany deficiency and is associated with vascular risk without establishing a specific causal relationship. Severe cytopenias may increase infectious or bleeding risk; reactive lymphoid hyperplasia is not a typical manifestation of vitamin B12 deficiency. When chronic deficiency remains unrecognized, general status may become markedly impaired, with progressive asthenia, apathy, loss of autonomy and worsening of chronic comorbidities, particularly cardiovascular and neurologic disorders.

Other manifestations

Skin hyperpigmentation may occur, particularly in the creases of the hands and feet, together with brittle nails, thin sparse hair and, in severe cases, skin or mucosal ulceration. In children, in addition to impaired linear and weight growth, hypothermia, thermoregulatory abnormalities and poor weight gain may occur.

Diagnosis and investigations

Diagnosis of vitamin B12 deficiency anemia requires an integrated and sequential approach based on careful correlation of clinical and laboratory data and, in uncertain cases, instrumental and genetic investigations. The presence of macrocytic anemia, with or without neurologic signs, is the first warning signal, but clinical suspicion should always be supported by a targeted history and complete assessment of individual and environmental risk factors.

The diagnostic work-up begins with laboratory confirmation of the hematologic picture: the complete blood count typically documents macrocytic anemia (MCV >100 fL), often associated with reticulocytopenia, leukopenia and thrombocytopenia. The peripheral smear shows macro-ovalocytes, poikilocytosis, anisocytosis and hypersegmented granulocytes (with nuclei containing 5 or more lobes), which are highly suggestive of megaloblastic deficiency. In chronic forms, a mild increase in indirect bilirubin due to ineffective erythropoiesis is common, together with elevated lactate dehydrogenase (LDH) due to intramedullary precursor lysis.

Direct serum vitamin B12 measurement is the first-line test: thresholds validated by the laboratory must be used; in their absence, values below 180 pg/mL indicate confirmed deficiency, values between 180 and 350 pg/mL are indeterminate and require further investigation, whereas values above 350 pg/mL make deficiency unlikely. When uncertainty remains, assessment of plasma homocysteine and urinary or serum methylmalonic acid is essential: both are elevated in vitamin B12 deficiency, often even in early stages and partially compensated forms, helping to distinguish B12 deficiency from folate deficiency, in which methylmalonic acid remains normal.

Concomitant folate deficiency should be considered in patients with megaloblastic anemia. Serum folate is generally the initial test; red-cell folate measurement is not routinely required and should be reserved for selected situations.

Once deficiency has been established, the underlying cause must be identified. The history should investigate:

• Dietary habits (vegan diet, dietary restriction, alcoholism)
• Previous gastrectomy, gastrointestinal surgery, chronic gastric or ileal disease
• Use of interfering drugs (proton pump inhibitors, H2 antagonists, metformin, colchicine)
• History of intestinal infections or parasitic infestations
• Family history of anemia or neuropathies

When pernicious anemia is suspected, testing includes anti-intrinsic factor antibodies (highly specific), anti-gastric parietal cell antibodies (more sensitive but less specific) and, in selected cases, gastroscopy with biopsy to document autoimmune atrophic gastritis and mucosal atrophy. When malabsorption is suspected, investigations should target the probable cause, for example celiac serology, ileal assessment or selected endoscopic and microbiologic studies; D-xylose testing and breath tests are not a routine panel for vitamin B12 deficiency.

Bone marrow examination is rarely necessary and is reserved for atypical cases or megaloblastic anemia without a definite diagnosis: biopsy typically shows erythroid hyperplasia, megaloblasts and dysmorphic nuclear-cytoplasmic maturation, without evidence of true myelodysplasia.

In children and infants with suspected congenital disorders of vitamin B12 metabolism (transcobalamin defects, mutations in conversion enzymes), specific genetic analyses and targeted metabolic assessments are performed, often with support from specialist metabolic centers.

Finally, neurologic assessment is crucial for early identification of subclinical neuropathy and monitoring clinical evolution. In selected cases, electromyography and nerve conduction studies can document peripheral neuropathy early, even in the absence of marked hematologic abnormalities.

In summary, diagnosis of vitamin B12 deficiency anemia is based on correlation of clinical findings, laboratory results and, when necessary, further investigations, with the aim of recognizing the condition early, identifying its cause and preventing irreversible complications, particularly those involving the nervous system.

Treatment and prognosis

Treatment of vitamin B12 deficiency anemia aims to correct the deficiency, resolve clinical manifestations and prevent irreversible complications, especially neurologic ones. Optimal management requires rapid identification of the cause, correction of the deficiency with appropriate therapeutic regimens, monitoring of response and prevention of recurrence, especially in chronic forms.

Correction of the deficiency: The treatment of choice is vitamin B12 administration (cyanocobalamin or hydroxocobalamin), with the route selected according to the severity of deficiency, the speed of correction required and the pathogenetic mechanism. In severe anemia, neurologic signs or established intestinal malabsorption, the parenteral route (intramuscular or subcutaneous) is preferred to ensure absorption independently of gastrointestinal function. A commonly used cyanocobalamin regimen is:

• Loading phase: 1000 mcg intramuscularly once daily for 7-10 days
• Consolidation phase: 1000 mcg 1-2 times per week for 1 month
• Maintenance: 1000 mcg monthly indefinitely in irreversible conditions (pernicious anemia, ileal resection, genetic disorders)

High-dose oral administration may also be effective in some malabsorption conditions through passive absorption independent of intrinsic factor. The choice between oral and intramuscular administration depends on the cause, clinical and neurologic severity, adherence and specific recommendations; in autoimmune gastritis, permanent replacement is generally required, often intramuscularly.

Monitoring response: Treatment efficacy is assessed clinically and through laboratory testing. Within a few days, a reticulocyte response occurs, followed by a gradual increase in hemoglobin, normalization of erythrocyte indices and resolution of anemic symptoms. Neurologic manifestations generally improve more slowly, and reversibility depends on how early correction is started: complete recovery is more likely when therapy is initiated promptly, whereas residual deficits may persist in chronic or severe cases.

Treatment of underlying causes and prevention of recurrence: The cause of deficiency must be identified and corrected:

• Patients following a strict vegan or vegetarian diet should receive regular vitamin B12 supplementation
• In pernicious anemia, replacement therapy is generally lifelong
• In reversible conditions (for example, use of interfering drugs, recovery from infection or resolution of transient malabsorption), maintenance therapy may be discontinued after normalization of vitamin levels and biochemical markers has been documented

In children and infants, early correction of deficiency is essential to prevent permanent impairment of neuropsychomotor development. Surveillance of the newborn breastfed by a vegan mother or a mother with unrecognized deficiency is of fundamental importance.

Management of complications: Transfusion of red blood cells is reserved for severe symptomatic anemia or hemodynamic compromise; platelets are indicated only for clinically relevant bleeding or according to established transfusion thresholds. Specific thromboembolic monitoring is not required for vitamin B12 deficiency alone.

Prognosis: The prognosis of vitamin B12 deficiency anemia is excellent when deficiency is recognized and corrected early, with complete recovery of hematologic and neurologic function in most cases. However, diagnostic delays or late treatment may leave permanent sequelae, especially neurologic ones, with risk of sensorimotor deficits and irreversible cognitive decline. Patients with pernicious anemia have an increased risk of gastric neoplasia; endoscopic surveillance should be individualized according to histologic findings and risk factors.

Prevention is based on nutritional education, surveillance of at-risk populations and supplementation when indicated. In children and pregnant women, monitoring of vitamin stores is essential to prevent long-term consequences.

Complications

The complications of vitamin B12 deficiency anemia are the main determinants of irreversible injury, long-term disability and impaired quality of life, especially when diagnosis is delayed or treatment is inadequate. These complications result both from prolonged cobalamin deficiency and from its downstream effects on multiple organ systems.

Hematologic complications: Prolonged deficiency can lead to severe pancytopenia, with risk of severe anemia, neutropenia and thrombocytopenia. In advanced cases, patients may develop recurrent or severe infections, mucocutaneous bleeding and, in frail patients, heart failure or myocardial ischemia because of inadequate tissue oxygen delivery. Untreated anemia may worsen pre-existing heart disease and increase mortality, particularly in older adults or in the presence of comorbidities.

Neurologic complications: Nervous system involvement is the most feared and potentially irreversible complication. If not treated promptly, subacute combined degeneration of the spinal cord can cause permanent sensorimotor deficits, loss of independent ambulation, chronic ataxia, sphincter disturbances (urinary and fecal incontinence), and even subacute dementia or progressive psychiatric disorders. In children, the risk of irreversible neuropsychomotor developmental delay and intellectual disability requires a preventive approach and diagnosis as early as possible.

Cardiovascular associations: Hyperhomocysteinemia is associated in observational studies with cardiovascular and thrombotic events, especially when other risk factors are present. This association does not prove that vitamin B12 deficiency directly causes those events or that correcting homocysteine systematically reduces their incidence.

Gastroenterologic and neoplastic complications: In pernicious anemia, chronic atrophic gastritis increases the risk of gastric carcinoma and gastric carcinoid tumors, so endoscopic surveillance should be defined according to histologic findings and individual risk. Chronic malabsorption may also promote concomitant deficiencies of other micronutrients (iron, folate, vitamin D).

Other complications: Chronic persistence of the condition may lead to hypothermia, skin fragility, mucosal ulcers, worsening of concomitant chronic diseases and an overall reduction in autonomy and quality of life. In older patients, the risk of falls, fractures and loss of self-sufficiency is significantly increased.

Prompt identification and correction of vitamin B12 deficiency is therefore crucial not only for resolving the hematologic picture but especially for preventing neurologic and systemic complications that, once established, may become largely irreversible. Multidisciplinary management and long-term follow-up are central to achieving the best possible outcome.

Bibliography
1. O'Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010;2(3):299–316.
2. Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149–160.
3. Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017;3:17040.
4. Herrmann W, Obeid R. Causes and early diagnosis of vitamin B12 deficiency. Dtsch Arztebl Int. 2008;105(40):680–685.
5. Andrès E, Affenberger S, Zimmer J, et al. Current hematological findings in cobalamin deficiency: a study of 201 consecutive patients with documented cobalamin deficiency. Clin Lab Haematol. 2006;28(1):50–56.
6. Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513.
7. Shipton MJ, Thachil J. Vitamin B12 deficiency - A 21st century perspective. Clin Med (Lond). 2015;15(2):145–150.
8. Yajnik CS, Deshpande SS, Lubree HG, et al. Vitamin B12 deficiency and hyperhomocysteinemia in rural and urban Indians. J Assoc Physicians India. 2006;54:775–782.
9. Allen LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull. 2008;29(2 Suppl):S20–S34.
10. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med. 1999;159(12):1289–1298.
11. Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. BMJ. 2014;349:g5226.
12. Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB. Postgraduate Haematology. Wiley-Blackwell. 7th ed. 2016.
13. Kaushansky K, et al. Williams Hematology. McGraw-Hill. 10th ed. 2021.
14. Greer JP, et al. Wintrobe’s Clinical Hematology. Wolters Kluwer. 14th ed. 2018.
15. National Institute for Health and Care Excellence. Vitamin B12 deficiency in over 16s: diagnosis and management (NG239). 2024.
16. Chan CQH, Low LL, Lee KH. Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia. Front Med (Lausanne). 2016;3:38.